secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001437749-24-026107
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma receives Nasdaq MVLS deficiency notice; must regain compliance by Feb 3, 2025
--------------------------------------------------------------------------------

- Nasdaq notified NRx on Aug 6 that MVLS was below $35M minimum from June 14 to Aug 5, 2024.
- Company has 180 days (until Feb 3, 2025) to achieve MVLS >= $35M for 10 consecutive days.
- Failure to regain compliance may result in delisting; Company can appeal but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924026107/0001437749-24-026107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924026107/nrxp20240812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer